Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-10-23 6:09 pm Purchase | 2024-10-16 | 13G | Bright Minds Biosciences Inc. DRUG | Logos Global Management LP | 100,000 2.200% | 100,000 (New Position) | Filing History |
| 2024-08-27 5:22 pm Purchase | 2024-03-14 | 13G | Cybin Inc. CYBN | Logos Global Management LP | 1,052,632 5.300% | 1,052,632 (New Position) | Filing History |
| 2024-08-13 6:53 pm Purchase | 2024-08-09 | 13D | Design Therapeutics, Inc. DSGN | Logos Global Management LP | 4,232,627 7.500% | 1,420,126 (+50.49%) | Filing History |
| 2024-06-06 6:49 pm Sale | 2024-06-04 | 13D | Olema Pharmaceuticals, Inc. OLMA | Logos Global Management LP | 3,248,818 5.800% | -1,018,130 (-23.86%) | Filing History |
| 2024-04-01 6:34 pm Purchase | 2024-04-01 | 13G | NextCure, Inc. NXTC | Logos Global Management LP | 166,705 7.200% | 166,705 (New Position) | Filing History |
| 2024-02-22 3:47 pm Purchase | 2024-02-06 | 13G | Adverum Biotechnologies, Inc. ADVM | Logos Global Management LP | 1,500,000 7.200% | 1,500,000 (New Position) | Filing History |
| 2024-02-14 4:01 pm Sale | 2023-12-31 | 13G | Allakos Inc. ALLK | Logos Global Management LP | 2,900,000 3.300% | -2,386,666 (-45.15%) | Filing History |
| 2024-02-14 3:51 pm Purchase | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Logos Global Management LP | 150,000 0.400% | 150,000 (New Position) | Filing History |
| 2024-02-13 7:31 pm Sale | 2023-12-31 | 13G | IDEAYA Biosciences, Inc. IDYA | Logos Global Management LP | 1,800,000 2.800% | -2,100,000 (-53.85%) | Filing History |
| 2024-02-13 7:23 pm Purchase | 2023-12-31 | 13G | Annexon, Inc. ANNX | Logos Global Management LP | 6,944,444 8.300% | 3,844,444 (+124.01%) | Filing History |
| 2024-01-22 4:57 pm Purchase | 2024-01-10 | 13G | Elevation Oncology, Inc. ELEV | Logos Global Management LP | 3,650,000 8.600% | 3,650,000 (New Position) | Filing History |
| 2024-01-22 4:27 pm Purchase | 2023-06-26 | 13G | Aeglea BioTherapeutics, Inc. AGLE | Logos Global Management LP | 3,469,927 9.900% | 3,469,927 (New Position) | Filing History |
| 2024-01-02 12:21 pm Purchase | 2023-12-19 | 13G | aTyr Pharma, Inc. ATYR | Logos Global Management LP | 5,800,000 9.900% | 5,800,000 (New Position) | Filing History |
| 2023-11-27 5:39 pm Purchase | 2023-09-12 | 13D | Olema Pharmaceuticals, Inc. OLMA | Logos Global Management LP | 4,266,948 7.800% | 508,130 (+13.52%) | Filing History |
| 2023-07-18 4:01 pm Purchase | 2023-07-06 | 13G | Aeglea BioTherapeutics, Inc. AGLE | Logos Global Management LP | 254,000 8.100% | 254,000 (New Position) | Filing History |
| 2023-06-22 1:25 pm Purchase | 2023-06-13 | 13G | Annexon, Inc. ANNX | Logos Global Management LP | 3,100,000 5.800% | 3,100,000 (New Position) | Filing History |
| 2023-02-14 4:23 pm Sale | 2022-12-31 | 13G | Allakos Inc. ALLK | Logos Global Management LP | 5,286,666 6.200% | -650,000 (-10.95%) | Filing History |
| 2023-02-14 4:14 pm Purchase | 2022-12-31 | 13G | IDEAYA Biosciences, Inc. IDYA | Logos Global Management LP | 3,900,000 8.100% | 3,900,000 (New Position) | Filing History |
| 2023-02-14 4:07 pm Sale | 2022-12-31 | 13G | Bicycle Therapeutics plc BCYC | Logos Global Management LP | 1,435,000 4.800% | -115,000 (-7.42%) | Filing History |
| 2023-02-14 3:53 pm Sale | 2022-12-31 | 13G | Dyne Therapeutics, Inc. DYN | Logos Global Management LP | 2,150,000 4.100% | -804,392 (-27.23%) | Filing History |